C Diff Drug Development

DelveInsight’s “Clostridium Difficile Infection (CDI) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Clostridium Difficile Infection (CDI), historical and forecasted epidemiology as well as the Clostridium Difficile Infection (CDI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. DelveInsight has launched a new […]

Clostridioides difficile infection (CDI) remains a significant health threat worldwide. C. difficile is an opportunistic, toxigenic pathogen that takes advantage of a disrupted gut microbiome to grow and produce signs and symptoms ranging from diarrhea to pseudomembranous colitis. Antibiotics used t …

Seres Therapeutics, Inc. announced that the company’s Phase III Ecospor IV study demonstrated a strong safety profile in addition to statistically significant positive results against C. difficile infection.

Shares of Seres Therapeutics Inc. undefined jumped 14.2% in premarket trading on Tuesday after the company shared data from a Phase 3 open-label study that...

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection.

In ECOSPOR III, the lead therapeutic candidate incorporated itself durably and rapidly into the microbiome to prevent recurrence, the company says.

Ken Blount, PhD, chief scientific officer at Rebiotix, discusses the investigative treatment RBX2660 and its unique approach to treating Clostridioides difficile infection.

SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.

Ten days after Finch Therapeutics let go 20% of its workforce, the winds have changed. | Ten days after Finch Therapeutics let go 20% of its workforce, the winds have changed. The FDA has lifted a clinical hold on the biotech’s donor-derived microbiome drug for Clostridioides difficile, clearing the way for a phase 3 study to proceed—eventually.

The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent bacterial threat. Yet, only two drugs, vancomycin and fidaxomicin, are approved by the FDA for the treatment of C. difficile infections as of this writing, while the global pipeline of n …

Clostridioides difficile is an opportunistic gut pathogen which causes severe colitis, leading to significant morbidity and mortality due to its toxins, TcdA and TcdB. Two intra-muscular toxoid vaccines entered Phase III trials and strongly induced toxin-neutralising antibodies systemically b …

A synthesized antibiotic derived from computer models of bacterial gene products appears to neutralize even drug-resistant bacteria. The compound, named cilagicin, works well in mice and employs a novel mechanism to attack MRSA, C. diff, and several other deadly pathogens.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

Using neutrons, researchers at Oak Ridge National Laboratory pieced together the molecular mechanics behind a peptide’s ability to deal significant damage to

Exploring the benefits of metal Ions in phage cocktail for the treatment of methicillin-resistant Staphylococcus aureus infection

RBX2660 was shown to be safe and effective at reducing recurrence in #Cdiff #infection - great talk by Paul Feuerstadt at #DDW2022 #microbes #treatment pic.twitter.com/1bEk8bxH3S— Mindy Engevik (@MicroMindy) May 24, 2022

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to

Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial.  | Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial. It hopes to present more data in May. The blueprint from the company comes after its shares have plummeted 50% in the last six months.

Hon Wai Koon is showing work that Bacillus velezensis secretes a metabolite that reduces #Cdiff #toxin B #intestinal damage #DDW2022 #microbes pic.twitter.com/lBG1c3DsQu— Mindy Engevik (@MicroMindy) May 24, 2022

The detection of resistant strains of Clostridioides difficile against existing antibiotics and the side effects led to the investigation of alternative agents. Inhibition zones of various essential oils to four strains of C.difficile and other Clostridium species ranged from 8.32-44.18 mm. The high …

Since the advent of penicillin more than 90 years ago, antibiotic drugs have saved countless lives by preventing and treating bacterial infections. However, bacteria are rapidly developing new ways to ...

Adiso Therapeutics, Inc. announced the completion of patient enrollment in the Phase 1b clinical study evaluating ADS024, an orally delivered single strain live biotherapeutic product, for the prevention of C. difficile infection recurrence.

A pair of posters presented at Digestive Disease Week 2022 showed the efficacy of an investigational biotherapeutic in preventing Clostridioides difficile infection recurrence and restoring the microbiome.

Investigational microbiota-based live therapeutic RBX2660 was found to be safe and effective at reducing Clostridioides difficile (C difficile) recurrence, said Paul Feuerstadt, MD, assistant clinical professor at Yale University School of Medicine, gastroenterologist at PACT Gastroenterology Center, at Digestive Disease Week 2022.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

SAN DIEGO RBX2660, an investigational live biotherapeutic, restored microbiome and bile acid composition concurrent with clinical response in patients with Clostridioides difficile, according to research at Digestive Disease Week 2022.“This poster is three different takes on how RBX2660 is aimed at restoring the microbiome and the data that we saw in three clinical trials,&rdq